Adaptive Biotechnologies (ADPT) vs Relay Therapeutics (RLAY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Relay Therapeutics (RLAY) has outperformed Adaptive Biotechnologies (ADPT) over the past year, gaining 184.9% versus a gain of 67.8%. Over five years, ADPT leads with a -22.1% price change compared with -49.0% for RLAY. Adaptive Biotechnologies is the larger company by market cap ($4.16 billion vs $3.82 billion), about 1.1 times the size.
Adaptive Biotechnologies converts more of its revenue into profit, with a net margin of -21.5% versus -1800.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADPT | RLAY |
|---|---|---|
| Share price | $26.09 | $17.41 |
| Market cap | $4.16B | $3.82B |
| 1-day change | -0.72% | -3.01% |
| YTD return | +60.65% | +105.79% |
| 1-year return | +67.78% | +184.94% |
| 5-year return | -22.12% | -48.96% |
| EPS (TTM) | $-0.41 | $-1.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $276.98M | $15.36M |
| Revenue growth (YoY) | +54.77% | +53.44% |
| Net income (latest FY) | $-59.50M | $-276.48M |
| Gross margin | 74.24% | — |
| Operating margin | -20.62% | -1971.59% |
| Net margin | -21.48% | -1800.58% |
| 52-week high | $30.74 | $21.27 |
| 52-week low | $12.00 | $5.85 |
| Distance from 52-week high | -15.13% | -18.15% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +8.51% | +58.41% |
| Average volume | 2.38M | 2.80M |
| Shares outstanding | 159.60M | 219.14M |
| Employees | 624 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLAY has outperformed ADPT by 117.2 percentage points over the past year.
- Adaptive Biotechnologies is more profitable, keeping -21.5 cents of every revenue dollar as net income versus -1800.6 cents for Relay Therapeutics.
About Adaptive Biotechnologies
ADPT stock →Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 624 employees
About Relay Therapeutics
RLAY stock →Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 202 employees
ADPT vs RLAY FAQ
Which is bigger, Adaptive Biotechnologies or Relay Therapeutics?
Adaptive Biotechnologies (ADPT) is larger, with a market capitalization of $4.16B compared with $3.82B for Relay Therapeutics (RLAY).
Which stock has performed better over the past year, ADPT or RLAY?
RLAY returned +184.94% over the past 12 months, compared with +67.78% for ADPT (price return, excluding dividends). Past performance does not predict future results.
Are Adaptive Biotechnologies and Relay Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.